Literature DB >> 23830990

An examination of cardiovascular collapse induced by eastern brown snake (Pseudonaja textilis) venom.

Janeyuth Chaisakul1, Geoffrey K Isbister, Sanjaya Kuruppu, Nicki Konstantakopoulos, Wayne C Hodgson.   

Abstract

The Pseudonaja genus (Brown snakes) is widely distributed across Australia and bites account for significant mortality. Venom-induced consumption coagulopathy (VICC) and, less often, early cardiovascular collapse occur following envenoming by these snakes. We have previously examined possible mechanism(s) behind the early cardiovascular collapse following Papuan taipan (Oxyuranus scutellatus) envenoming. In the present study, we investigate early cardiovascular collapse in anaesthetized rats following administration of eastern brown snake (Pseudonaja textilis) venom, and prevention of this effect with prior administration of 'priming' doses (i.e. doses of venom which caused a transient hypotensive response) of venom. P. textilis venom (5-10 μg/kg, i.v.) induced cardiovascular collapse in anaesthetized rats, characterized by a rapid decrease in systolic blood pressure until non recordable. Prior administration of 'priming' doses of P. textilis venom (2 and 3 μg/kg) or, at least, 4-5 doses of O. scutellatus (2 μg/kg, i.v.) or Daboia russelii limitis (20 μg/kg, i.v.) venoms prevented cardiovascular collapse induced by P. textilis venom. Moreover, early collapse was also inhibited by prior administration of 2 discrete doses of Acanthophis rugosus venom. Prior administration of commercial polyvalent snake antivenom (500-3000 units/kg, i.v.) or heparin (300 units/kg, i.v.) also inhibited P. textilis venom-induced cardiovascular collapse. Our results indicate that P. textilis venom-induced cardiovascular collapse can be prevented by prior administration of sub-lethal doses of venom from P. textilis, O. scutellatus, A. rugosus and D. russelii limitis. This suggests that sudden cardiovascular collapse following envenoming is likely to involve a common mechanism/pathway activated by different snake venoms.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ANOVA; Anaesthetized rat; Antivenom; Brown snake; Cardiovascular collapse; HRP; MAP; PVDF; TBST; Tris-buffered saline and Tween 20.; Venom; analysis of variance; horseradish peroxidase; i.p.; i.v.; intraperitoneal administration; intravenous administration; mean arterial pressure; polyvinylidene difluoride

Mesh:

Substances:

Year:  2013        PMID: 23830990     DOI: 10.1016/j.toxlet.2013.06.235

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  4 in total

1.  A Pharmacological Examination of the Cardiovascular Effects of Malayan Krait (Bungarus candidus) Venoms.

Authors:  Janeyuth Chaisakul; Muhamad Rusdi Ahmad Rusmili; Wayne C Hodgson; Panadda Hatthachote; Kijja Suwan; Anjaree Inchan; Lawan Chanhome; Iekhsan Othman; Krongkarn Chootip
Journal:  Toxins (Basel)       Date:  2017-03-29       Impact factor: 4.546

2.  D. russelii Venom Mediates Vasodilatation of Resistance Like Arteries via Activation of Kv and KCa Channels.

Authors:  Rahini Kakumanu; Sanjaya Kuruppu; Lachlan D Rash; Geoffrey K Isbister; Wayne C Hodgson; Barbara K Kemp-Harper
Journal:  Toxins (Basel)       Date:  2019-04-01       Impact factor: 4.546

3.  Comparative compositional and functional venomic profiles among venom specimens from juvenile, subadult and adult Russell's viper ( Daboia siamensis ): correlation with renal pathophysiology in experimental rabbits.

Authors:  Narongsak Chaiyabutr; Lawan Chanhome; Taksa Vasaruchapong; Panithi Laoungbua; Orawan Khow; Anudep Rungsipipat; Onrapak Reamtong; Visith Sitprija
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2022-04-04

4.  An in vivo examination of the differences between rapid cardiovascular collapse and prolonged hypotension induced by snake venom.

Authors:  Rahini Kakumanu; Barbara K Kemp-Harper; Anjana Silva; Sanjaya Kuruppu; Geoffrey K Isbister; Wayne C Hodgson
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.